Last reviewed · How we verify
Brimonidine, pilocarpine
At a glance
| Generic name | Brimonidine, pilocarpine |
|---|---|
| Also known as | Mirvaso; Alphagan P; Salagen; Isopto Carpine |
| Sponsor | Massachusetts Eye and Ear Infirmary |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Superior vs Temporal Laser Peripheral Iridotomy in Primary Angle Closure Suspects (PACS) (NA)
- A Novel Argon Laser Iridoplasty for Pigment Dispersion Syndrome (NA)
- PSLT Compared to Prostaglandin Analogue Eye Drops (NA)
- Compound to Control Presbyopia Symptoms (PHASE1)
- Comparison of a Compound With Pilocarpine and Brimonidine to Improve Near Vision in Healthy Presbyopic Patients (PHASE1)
- Pilocarpine, Brimonidine, Oxymetazoline (PBO) Compound to Control Presbyopia Symptoms (PHASE1)
- Pilocarpine and Brimonidine in Patients With Monofocal Lenses (EARLY_PHASE1)
- Randomized Prospective Study of Selective Laser Trabeculoplasty (SLT) Versus Argon Trabeculoplasty (ALT) in Patients With Pseudoexfoliation Glaucoma and Ocular Hypertension (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brimonidine, pilocarpine CI brief — competitive landscape report
- Brimonidine, pilocarpine updates RSS · CI watch RSS
- Massachusetts Eye and Ear Infirmary portfolio CI